Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Specialist pharmaceuticals company N4 Pharma recorded an operating loss of £585,066 for the first half of 2020.
This was an improvement on the H1 2019 operating loss of £552,160, mainly driven by lower general and administration costs.
The company's Nuvec product, which is designed to deliver vaccines and cancer treatments, was successfully tested in connection with COVID-19 work as N4 Pharma redirected its efforts towards the pandemic.
During the period, the company raised £1.9m through a share issue, raising its cash level to £2.4m.
At 9:07am: (LON:N4P) N4 Pharma Plc Ord 0.4p share price was 0p at 6.25p